Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03837743 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis
A Phase 2 study, sponsored by Durect.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT03837743 is a Phase 2 study that has completed, run by Durect. The registered enrollment target is 25 participants.
The verdict
NCT03837743, a Phase 2 study, has completed, sponsored by Durect.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This Phase 2 study has been designed to determine and compare the safety, tolerability, and efficacy of DUR-928 topical solution with that of the vehicle topical solution when applied once daily for approximately four weeks in subjects with plaque psoriasis. Subjects will be instructed (randomly assigned) to apply DUR-928 solution to a target lesion on one arm and vehicle solution to a target lesion on the opposite arm once daily for up to four weeks. Subjects will occlude the treated areas for approximately two hours after each application.
Interventions
- DRUG DUR-928 Topical Solution
- DRUG Vehicle Topical Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-02-21 |
| Est. Completion | 2020-05-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03837743
The ClinicalTrials.gov registry entry for NCT03837743 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Durect, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DUR-928 Topical Solution is the first listed.
NCT03837743 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03837743 about?
NCT03837743 is a clinical study titled "Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis". This Phase 2 study has been designed to determine and compare the safety, tolerability, and efficacy of DUR-928 topical solution with that of the vehicle topical solution when applied once daily for approximately four weeks in subjects with plaque psoriasis. Subjects will be instructed (randomly ass...
What is the current status of trial NCT03837743?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2019-02-21. Estimated completion is 2020-05-20.
What interventions are being tested in trial NCT03837743?
The interventions under investigation include: DUR-928 Topical Solution (DRUG), Vehicle Topical Solution (DRUG).
Who is sponsoring clinical trial NCT03837743?
This trial is sponsored by Durect, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.